saveJANSSEN:Layout 1
9-04-2014
17:17
Pagina 1
save
the date
13:15-14:15
Italian
Conference on
AIDS and
Retroviruses
ROMA,
25-27 MAGGIO
2014
SHERATON
CONFERENCE
CENTER
Lunedì 26
PI and PI in the
Moderatore: A. Antinorimanagement
(Roma)
of
infectious diseases
Unrestricted educational grant di
Speakers:
H. Hinrichsen (Kiel, D), A.L. Pozniak (London, UK)
Discussants:
A. d’Arminio Monforte (Milan, I), M. Galli (Milan, I)
maggio 2014
Sito web del Congresso ICAR
www.icar2014.it
EXPERT
MEETING
Provider e
Segreteria Organizzativa
Effetti Srl
Via Gallarate, 106 - 20151 Milano
Ref. Barbara Bocciardi
Tel. 02 3343281 - Fax 02 33496370
E-mail: [email protected]
www.effetti.it
ICAR
VI CONGRESSO NAZIONALE
saveJANSSEN:Layout 1
9-04-2014
17:17
Pagina 3
Gentile Dottoressa, Egregio Dottore,
Scientific Programme
La partecipazione alla sessione è a numero chiuso e riservata agli Specialisti iscritti
al Congresso. La preghiamo pertanto di ritornarci compilata la scheda di adesione
allegata per la conferma dell’iscrizione.
PI and PI in the management
of infectious diseases
RingraziandoLa anticipatamente, Le porgiamo i più cordiali saluti.
Il Provider
Effetti Srl
Faculty
EXPERT
MEETING
Antonella d’Arminio Monforte San Paolo Hospital, University of Milan, I
Massimo Galli Luigi Sacco Hospital, University of Milan, I
Holger Hinrichsen Gastroenterologisch-Hepatologisches Zentrum, Kiel, D
Anton Louis Pozniak Chelsea and Westminster Hospital – NHS Foundation Trust, London UK
Moderatore: A. Antinori (Roma)
VI CONGRESSO NAZIONALE
ICAR
Italian
Conference on
AIDS and
Retroviruses
save the
date
save
the date
Lunedì
26
Protease inhibitors can be considered the “core” agents of both HIV and HCV therapy, actually the most common infectious
diseases impacting on patients’ life and in clinical practice for their comorbidities burden. In HIV, DRV is the third agent allowing
a real tailored therapy for its important successful data obtained in association with other various “companion” drugs. In fact, it
has not only shown its efficacy in monotherapy RCTs but it has proved to be an ideal third agent, superior to PI competitors, in
triple therapy (with ABC/3TC or TDF/FTC) as well as in dual therapy strategies (with RAL, MVC, ETR, 3TC) and also in the
ongoing studies with RPV and, more recently, with DTG (NEAT Study). In hepatitis C, moving from settled efficacy data in real
world practice obtained by telaprevir (or BOC) + PR, which contributed to confirm its role as SOC, we will focus on second
generation PI, simeprevir, in terms of superior efficacy and safety profile. SIM, the first new PI to be marketed in hepatitis C
therapy, has shown efficacy and safety data in HCV1 and HCV4 with PR and, in combination with SOF, in HCV naïve F3 and
F4 and NR F0-F4 (COSMO Study) and in phase II study in combination with DCV. Looking to recent pipelines, HCV protease
inhibitors can be defined as the “sine qua non” agents in HCV therapy.
Discussants: A. d’Arminio Monforte (Milan, I), M. Galli (Milan, I)
13.15-13.45
Which strategies in HIV? A.L. Pozniak (London, UK)
13.45-14.15
Which strategies in HCV? H. Hinrichsen (Kiel, D)
maggio 2014
Abbiamo il piacere di invitarLa a partecipare all’EXPERT MEETING “PI and PI in
the management of infectious diseases” che si terrà lunedì 26 maggio 2014
dalle ore 13.15 alle ore 14.15, organizzato nell’ambito del 6° Congresso ICAR.